314 related articles for article (PubMed ID: 27729614)
1. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract][Full Text] [Related]
2. High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.
van den Broek E; Dijkstra MJ; Krijgsman O; Sie D; Haan JC; Traets JJ; van de Wiel MA; Nagtegaal ID; Punt CJ; Carvalho B; Ylstra B; Abeln S; Meijer GA; Fijneman RJ
PLoS One; 2015; 10(9):e0138141. PubMed ID: 26375816
[TBL] [Abstract][Full Text] [Related]
3. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
5. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Shen Y; Han X; Wang J; Wang S; Yang H; Lu SH; Shi Y
Sci Rep; 2016 Apr; 6():24310. PubMed ID: 27074743
[TBL] [Abstract][Full Text] [Related]
7. Focus on 16p13.3 Locus in Colon Cancer.
Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
[TBL] [Abstract][Full Text] [Related]
8. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
[TBL] [Abstract][Full Text] [Related]
9. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
10. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
[TBL] [Abstract][Full Text] [Related]
11. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
13. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients.
Conconi D; Redaelli S; Bovo G; Leone BE; Filippi E; Ambrosiani L; Cerrito MG; Grassilli E; Giovannoni R; Dalprà L; Lavitrano M
Tumour Biol; 2016 Oct; 37(10):13831-13842. PubMed ID: 27481518
[TBL] [Abstract][Full Text] [Related]
14. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
15. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
[TBL] [Abstract][Full Text] [Related]
16. Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.
Sefrioui D; Vermeulin T; Blanchard F; Chapusot C; Beaussire L; Armengol-Debeir L; Sesboué R; Gangloff A; Hebbar M; Copin MC; Houivet E; Schwarz L; Clatot F; Tuech JJ; Bénichou J; Martin L; Bouvier AM; Sabourin JC; Sarafan-Vasseur N; Frébourg T; Lepage C; Michel P; Di Fiore F
Int J Cancer; 2017 Apr; 140(7):1653-1661. PubMed ID: 28006840
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
18. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
[TBL] [Abstract][Full Text] [Related]
19. Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.
Lahoz S; Archilla I; Asensio E; Hernández-Illán E; Ferrer Q; López-Prades S; Nadeu F; Del Rey J; Sanz-Pamplona R; Lozano JJ; Castells A; Cuatrecasas M; Camps J
J Pathol; 2022 May; 257(1):68-81. PubMed ID: 35066875
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
